Stage IIIA Bladder Cancer AJCC v8 Clinical Trials

5 recruitingLast updated: June 18, 2026

There are 5 actively recruiting stage iiia bladder cancer ajcc v8 clinical trials across 1 country. Studies span Phase 2, Phase 1, Phase 3. Top locations include Billings, Montana, United States, Bloomington, Illinois, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Stage IIIA Bladder Cancer AJCC v8 Trials at a Glance

5 actively recruiting trials for stage iiia bladder cancer ajcc v8 are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Billings, Bloomington, and Ann Arbor. Lead sponsors running stage iiia bladder cancer ajcc v8 studies include Mayo Clinic, NRG Oncology, and National Cancer Institute (NCI).

Browse stage iiia bladder cancer ajcc v8 trials by phase

Treatments under study

About Stage IIIA Bladder Cancer AJCC v8 Clinical Trials

Looking for clinical trials for Stage IIIA Bladder Cancer AJCC v8? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stage IIIA Bladder Cancer AJCC v8 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stage IIIA Bladder Cancer AJCC v8 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled143 locationsNCT07061964
Recruiting
Phase 3

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
NRG Oncology486 enrolled211 locationsNCT07097142
Recruiting

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Stage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage 0a Bladder Cancer AJCC v8+2 more
Mayo Clinic704 enrolled3 locationsNCT06350734
Recruiting
Phase 1Phase 2

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaBladder CancerStage II Bladder Cancer AJCC v8+1 more
University of California, San Francisco47 enrolled1 locationNCT06470282
Recruiting
Phase 2

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Muscle-Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8+1 more
Yuanquan Yang24 enrolled3 locationsNCT06263153